Vision of Pfe becoming a small high flying biotech stock sounds wonderful as Abbvie changed name and spun off business and did just that few yrs ago.
Problem is Pfizer leadership and brain trust is not Abbvie!
Wall Street agrees and does not see Pfe coming a hot biotech as they are selling the stock from 46 to 36. Not good start first 18months for new European CEO.
If stock gets to down 33, BOD will need to oust him.
Problem is Pfizer leadership and brain trust is not Abbvie!
Wall Street agrees and does not see Pfe coming a hot biotech as they are selling the stock from 46 to 36. Not good start first 18months for new European CEO.
If stock gets to down 33, BOD will need to oust him.